No connection

Search Results

MASI

BEARISH
$178.47 Live
Masimo Corporation · NASDAQ
Target $180.0 (+0.9%)
$125.94 52W Range $179.0
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026
Market cap
$9.35B
P/E
46.6
ROE
23.4%
Profit margin
-9.9%
Debt/Equity
0.78
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
MASI exhibits a severe valuation disconnect, trading at $178.47 despite a Graham Number of $34.54 and an Intrinsic Value of $26.81. While the Piotroski F-Score of 4/9 indicates stable financial health, the company is struggling with a negative profit margin (-9.92%) and a concerning Q/Q revenue collapse of -31.33%. Strong gross margins and ROE are offset by a significant YoY EPS decline of -31.7% and bearish insider sentiment. The stock is currently priced for perfection in a deteriorating short-term growth environment.

Key Strengths

Strong Gross Margin (61.80%) indicating high product value
Robust Return on Equity (ROE) of 23.43%
Healthy liquidity with a Current Ratio of 2.49
Manageable Debt/Equity ratio of 0.78
Consistent historical track record of beating earnings estimates

Key Risks

Extreme overvaluation relative to Graham and Intrinsic value models
Sharp Q/Q revenue contraction (-31.33%)
Significant YoY earnings decline (-31.7%)
Negative net profit margin (-9.92%)
Strongly bearish technical trend (10/100) and insider selling
AI Fair Value Estimate
Based on comprehensive analysis
$35.2
-80.3% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
35
Weak
Value
15
Future
40
Past
65
Health
55
Dividend
0
AI Verdict
Overvalued / High Risk
Key drivers: Valuation gap, Q/Q Revenue decline, Negative profit margins
Confidence
90%
Value
15/100

Ref P/E 46.60, Graham Number $34.54

Positives
  • Forward P/E (27.04) is lower than trailing P/E
Watchpoints
  • Price/Book of 12.89 is excessive
  • Trading ~5x above Graham Number
  • P/S ratio of 6.12 is high for current growth rates
Future
40/100

Ref Growth rates

Positives
  • YoY Revenue growth remains positive at 12%
Watchpoints
  • Severe Q/Q revenue drop (-31.33%)
  • YoY EPS growth is deeply negative (-31.7%)
Past
65/100

Ref Historical trends

Positives
  • Long-term history of earnings beats
  • Strong historical ROE
Watchpoints
  • 5-year price change is negative (-25.5%)
Health
55/100

Ref Piotroski F-Score 4/9

Positives
  • Current Ratio 2.49
  • Low Debt/Equity 0.78
Watchpoints
  • Piotroski F-Score is only 4/9 (Stable, not Strong)
  • Negative net profit margin
Dividend
0/100

Ref Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$178.47
Analyst Target
$180.0
Upside/Downside
+0.9%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MASI and closest competitors.

Updated 2026-04-13
MAS
Masimo Corporation
Primary
5Y
-25.5%
3Y
-6.9%
1Y
+16.2%
6M
+20.6%
1M
+1.7%
1W
-0.0%
AXS
Axsome Therapeutics, Inc.
Peer
5Y
+146.1%
3Y
+162.6%
1Y
+79.0%
6M
+84.4%
1M
+21.0%
1W
+4.9%
BIO
Bio-Rad Laboratories, Inc.
Peer
5Y
-47.0%
3Y
-22.7%
1Y
-10.4%
6M
+26.6%
1M
+0.7%
1W
+0.7%
BAX
Baxter International Inc.
Peer
5Y
-77.7%
3Y
-54.7%
1Y
-49.6%
6M
-27.5%
1M
-14.1%
1W
-1.2%
HSI
Henry Schein, Inc.
Peer
5Y
+7.6%
3Y
-11.6%
1Y
+18.5%
6M
+19.3%
1M
-1.5%
1W
+1.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
46.6
Forward P/E
27.04
PEG Ratio
N/A
P/B Ratio
12.89
P/S Ratio
6.12
EV/Revenue
6.37
EV/EBITDA
28.16
Market Cap
$9.35B

Profitability

Profit margins and return metrics

Profit Margin -9.92%
Operating Margin 18.52%
Gross Margin 61.8%
ROE 23.43%
ROA 8.86%

Growth

Revenue and earnings growth rates

Revenue Growth +12.0%
Earnings Growth N/A
Q/Q Revenue Growth -31.33%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.78
Moderate
Current Ratio
2.49
Strong
Quick Ratio
1.29
Good
Cash/Share
$2.92

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.4B
Gross Margin
60.0%
Op. Margin
20.3%
Net Margin
16.6%
Total Assets
$1.7B
Liabilities
$1.0B
Equity
$0.7B
Debt/Equity
1.36x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
86%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-02-27
$1.23
-4.7% surprise
2025-11-04
$1.32
+9.9% surprise
2025-08-05
$1.33
+8.8% surprise

Healthcare Sector Comparison

Comparing MASI against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)
P/E Ratio
46.6
This Stock
vs
88.11
Sector Avg
-47.1% (Discount)
Return on Equity (ROE)
23.43%
This Stock
vs
-86.0%
Sector Avg
-127.2% (Below Avg)
Profit Margin
-9.92%
This Stock
vs
-11.76%
Sector Avg
-15.6% (Weaker)
Debt to Equity
0.78
This Stock
vs
3.51
Sector Avg
-77.9% (Less Debt)
Revenue Growth
12.0%
This Stock
vs
90.15%
Sector Avg
-86.7% (Slower)
Current Ratio
2.49
This Stock
vs
3.67
Sector Avg
-32.0% (Weaker)

Similar Companies

Peer comparison within the same industry

MASI Masimo Corporation
BEARISH
Mkt Cap
$9.3B
P/E
46.6
ROE
23.4%
Price
$178.47
AXSM Axsome...
BEARISH
Mkt Cap
$9.4B
P/E
-
ROE
-275.5%
Price
$185.96
 Compare with MASI
BIO-B Bio-Rad...
BEARISH
Mkt Cap
$9.8B
P/E
-
ROE
-9.5%
Price
$312.75
 Compare with MASI
BAX Baxter...
BEARISH
Mkt Cap
$8.7B
P/E
-
ROE
-13.7%
Price
$16.91
 Compare with MASI
HSIC Henry Schein, Inc.
BULLISH
Mkt Cap
$8.6B
P/E
23.0
ROE
8.7%
Price
$75.34
 Compare with MASI

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

SZYMAN CATHERINE M
Chief Executive Officer
Stock Award
2026-03-11
2,101 shares
YOUNG MICAH W
Chief Financial Officer
Stock Award
2026-03-11
873 shares
YOUNG MICAH W
Chief Financial Officer
Stock Award
2026-02-27
15,000 shares
YOUNG MICAH W
Chief Financial Officer
Option Exercise
2026-02-27
15,000 shares · $2,630,250
YOUNG MICAH W
Chief Financial Officer
Stock Award
2026-02-26
2,034 shares
SZYMAN CATHERINE M
Chief Executive Officer
Option Exercise
2026-02-12
11,141 shares · $1,481,307
SAMPATH ANAND
Officer
Sell
2026-01-28
18,680 shares · $2,555,570
SAMPATH ANAND
Officer
Option Exercise
2026-01-28
30,000 shares · $1,135,200
AHMED OMAR
Chief Technology Officer
Option Exercise
2025-11-13
2,474 shares · $377,112
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
HOLD
4 analysts
Raymond James
2026-03-27
down
Outperform Market Perform
Wells Fargo
2026-02-18
down
Overweight Equal-Weight
BTIG
2026-02-18
down
Buy Neutral
BTIG
2025-12-04
Maintains
Buy Buy
BTIG
2025-11-24
reit
Buy Buy
B of A Securities
2025-11-17
init
Neutral
Wells Fargo
2025-11-05
Maintains
Overweight Overweight
BTIG
2025-11-05
reit
Buy Buy

Past News Coverage

Recent headlines mentioning MASI from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile